|
Apr 10
|
Vertex Pharma boosts immunotherapy business in $4.9 billion Alpine Immune deal
|
|
Apr 10
|
UPDATE 2-Vertex Pharma boosts immunotherapy business in $4.9 bln Alpine Immune deal
|
|
Apr 10
|
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
|
|
Apr 10
|
Vertex to buy kidney disease drugmaker Alpine for $4.9B
|
|
Apr 10
|
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
|
|
Apr 9
|
Vertex to Announce First Quarter 2024 Financial Results on May 6
|
|
Apr 9
|
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
|
|
Apr 9
|
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
|
|
Apr 9
|
11 Best Biotech ETFs To Buy
|
|
Apr 9
|
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
|
|
Apr 5
|
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
|
|
Apr 4
|
3 Underappreciated Healthcare Stocks to Buy Now: April 2024
|
|
Apr 3
|
Insider Sell: SVP & Chief Accounting Officer Kristen Ambrose Sells Shares of Vertex ...
|
|
Apr 3
|
Vertex Is Worth Your Attention
|
|
Apr 2
|
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
|
|
Apr 1
|
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
Apr 1
|
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
|
|
Apr 1
|
Vertex moves kidney disease drug into late-stage testing
|
|
Apr 1
|
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
|
|
Apr 1
|
Meet The "Magnificent Seven" of Healthcare Stocks
|